*ROR score is Prosigna’s proprietary model for predicting risk of recurrence in a patient. Probability of recurrence cannot be guaranteed.
Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013.
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol
. 2009;27(8):1160-1167. 3.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature
. 2000;406(6797):747-752. 4.
Bastien RRL, Ebbert MTW, Boucher KM, et al. Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: a direct comparison to Oncotype
DX. Presented at: 47th American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL. Abstract 503. 5.
Nielsen T, McDonald S, Kulkarni S, et al. Analytical reproducibility of the breast cancer intrinsic subtyping test and nCounter®
Analysis System using formalin-fixed paraffin-embedded (FFPE) breast tumor specimens. Poster presented at: 102nd United States and Canadian Academy of Pathology Annual Meeting; March 2-8, 2013; Baltimore, MD. Abstract 2075. 6.
Gnant M, Filipits M, Mlineritsch B, et al; Austrian Breast and Colorectal Cancer Study Group. Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with HR+ early breast cancer (EBC): an ABCSG study. Presented at: San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Abstract P2-10-02.